Steatosis of Liver
22
4
5
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 22 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (22)
Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
Biomarkers of Steatohepatitis in Type 2 Diabetes Patients
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ultrasound Index Fat Fraction
LITMUS Imaging Study
Study of Eating Patterns with a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
Quantitative CT Imaging Parameters for Assessing Hepatic Steatosis in CHB
Ultrasound and Attenuation Imaging
Ketogenic Diet in MASLD-related cACLD
Global Research Initiative for Patients Screening on MASH
Effect of 4 Weeks of Oral D. Piger on Safety, Pharmacokinetics and Ethanol Metabolism in Overweight Individuals (2023)
Prevalence of Steatosis and Steatohepatitis in Patients Undergoing Bariatric Surgery; a Biopsy-based Study
Assessment the Diagnostic Value of Pro-Neurotensin as a Serum Biomarker in MASLD
Comparison of MRI-PDFF to TAEUS FLIP Device to Estimate Liver Fat Fraction in Adults
Liver Fat and Glucagon Resistance
The Role of Immune Semaphorins in Steatotic Liver Disease and Sepsis
CT Liver Fat Fraction Quantification
The European NAFLD Registry
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
The Liver in the World Trade Center Health Program General Responder Cohort and Controls